Group 1: Business Performance and Revenue - In 2024, the company achieved sales revenue of CNY 58,804.95 million for contrast agents, a year-on-year increase of 9.87% [1] - Sales revenue for hypoglycemic products reached CNY 12,598.34 million, growing by 33.24% year-on-year [1] - The company reported a decline in raw material sales revenue to CNY 9,003.14 million, down by 20.83% [1] - Sales revenue for traditional Chinese medicine preparations was CNY 16,844.68 million, reflecting a year-on-year growth of 19.65% [1] - The company’s overseas revenue for 2024 was CNY 13,216.14 million, marking a 15.02% increase [4] Group 2: Strategic Developments - The company continues to implement a "chemical + traditional Chinese medicine" dual-driven strategy, focusing on contrast agents, hypoglycemic drugs, and central nervous system traditional Chinese medicine [1] - The construction of the Cangzhou Phase III raw material production project has been completed, enhancing the production capacity for gadolinium and iodine contrast agents [2] - The Bozhou production base is progressing, with the first phase expected to start trial production and process validation within the year [3] Group 3: Market Expansion and Product Development - The company is expanding its market presence internationally, with successful exports of contrast agents and raw materials to South America, Africa, and Asia [4] - The company’s subsidiary, Haichang Pharmaceutical, is one of the few domestic producers with iodine contrast agent production qualifications, with an annual capacity of 1,000 tons [2] - The "MERCURY non-invasive blood test" technology developed by the affiliated company, Shihe Gene, allows for the screening of nine types of cancer from a single blood sample [7]

Group 1 - The Alzheimer's concept sector declined by 0.90%, ranking among the top declines in the concept sector, with notable declines from companies such as Wanbangde, Tonghua Jinma, and Kanghong Pharmaceutical [1][2] - Among the stocks in the Alzheimer's concept sector, 9 stocks experienced price increases, with Beilu Pharmaceutical, Lisheng Pharmaceutical, and Haizheng Pharmaceutical leading the gains at 4.42%, 3.36%, and 1.77% respectively [1][2] - The Alzheimer's concept sector saw a net outflow of 408 million yuan from major funds, with 22 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 30 million yuan, led by Tonghua Jinma with a net outflow of 126 million yuan [2][3] Group 2 - The top net inflow stocks in the Alzheimer's concept sector included Beilu Pharmaceutical, Luhua Pharmaceutical, and Meinian Health, with net inflows of 23.6 million yuan, 14.7 million yuan, and 14.2 million yuan respectively [2][3] - The stocks with the highest net outflows in the Alzheimer's concept sector included Tonghua Jinma, Changchun Gaoxin, and Dian Diagnostics, with net outflows of 125.8 million yuan, 53.6 million yuan, and 51.5 million yuan respectively [2][3] - The trading activity in the Alzheimer's concept sector showed significant turnover rates, with stocks like Tonghua Jinma and Wanbangde having turnover rates of 4.80% and 15.18% respectively [2][3]

Core Viewpoint - The article highlights the ongoing issues with the timely supply of drugs and medical devices following centralized procurement in various regions of China, indicating a significant number of products have not established delivery relationships post-selection, which raises concerns about the reliability of selected suppliers [1][9]. Group 1: Issues with Drug Supply - As of May 31, 2023, 443 drug specifications have not established timely delivery relationships after centralized procurement in Guangzhou, with nearly 70% of the 221 identified underperforming products having a delivery rate of 0 [9][10]. - The Hebei Provincial Medical Procurement Center has announced that certain companies will be rated as "generally" untrustworthy due to inadequate delivery services, including Suzhou Terui Pharmaceutical and Lizu Group, which are involved in multiple national procurement batches [2][5]. Group 2: Specific Products and Companies - Lizu Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, a significant drop from its previous market price of 700-800 yuan, reflecting a price reduction of over 90% [2]. - Northland Pharmaceutical's iohexol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [3]. Group 3: Regulatory Framework and Consequences - The Hebei Provincial Medical Procurement Center has established a credit evaluation system for pharmaceutical pricing and procurement, categorizing untrustworthy behavior into four levels: "general," "medium," "serious," and "particularly serious" [7]. - Companies identified as untrustworthy may face consequences such as written warnings, risk notifications on procurement platforms, and restrictions on the procurement qualifications of related drugs and materials [7]. Group 4: Broader Supply Issues - Beyond medical institutions, there are also reported supply shortages in designated pharmacies, with 422 drugs not supplied, affecting various products and involving 289 manufacturers [8].

Core Viewpoint - The announcement from the Hebei Provincial Medical Supplies Procurement Center indicates that several companies are being rated as "generally" untrustworthy due to inadequate delivery services for selected products in the national centralized procurement process [1][2][3] Group 1: Companies Involved - Companies listed for potential untrustworthiness include Suzhou Terui Pharmaceutical, Sihuan Pharmaceutical, Lijun Group, Jiangxi Yongfeng Kande Pharmaceutical, Guangdong Saifeng Pharmaceutical, Beijing Fule Technology, and Beijing Beilu Pharmaceutical [1][2] - Lijun Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, down from a previous market price of 700-800 yuan, representing a price drop of over 90% [1] - Beilu Pharmaceutical's iopamidol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [1] Group 2: Regulatory Framework - The Hebei Provincial Medical Security Bureau established a credit evaluation system for drug pricing and procurement in late 2020, categorizing untrustworthy behavior into four levels: "general," "moderate," "serious," and "particularly serious" [3] - The "general" untrustworthiness rating applies to companies that fail to fulfill procurement or delivery contracts without valid reasons and do not notify procurement agencies in advance, provided it does not severely impact clinical treatment [3] - Once a company is rated as untrustworthy, the provincial procurement center will implement measures such as written warnings, risk notifications on procurement platforms, and restrictions on procurement qualifications [3] Group 3: Broader Industry Context - The issue of supply shortages is not limited to medical institutions; designated pharmacies in Hebei also face significant shortages, with 422 drugs reported as unavailable [4] - Other regions, including Liaoning, Hainan, and Guangzhou, have also reported issues with selected companies failing to deliver drugs on time since the implementation of centralized procurement policies [4] - As of May 31, 2023, 443 drug varieties had not established timely delivery relationships post-procurement, with nearly 70% of the identified varieties having a delivery rate of 0% [4] Group 4: Future Developments - By the end of 2024, 612 companies were rated as generally untrustworthy, 76 as moderately untrustworthy, 40 as seriously untrustworthy, and 7 as particularly seriously untrustworthy [5] - A new standard for credit evaluation will be implemented starting from the third quarter of 2025, simplifying the rating system from four levels to three: "untrustworthy," "seriously untrustworthy," and "particularly seriously untrustworthy" [6]

股票代码：300016 股票简称：北陆药业 公告编号：2025-056 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于董事会完成换届选举、聘任高级管理人员 及证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日召开 2025 年第二次临时股东大会，选举产生了公司第九届董事会非独立董事 5 名、 独立董事 3 名，与公司职工代表大会选举产生的职工代表董事 1 名，共同组成 了公司第九届董事会。同日，公司召开第九届董事会第一次会议，审议通过了 选举公司第九届董事会董事长、董事会各专门委员会委员、聘任高级管理人员 及证券事务代表相关议案。现将有关事项公告如下： 一、公司第九届董事会及各专门委员会组成情况 （一）第九届董事会成员 公司第九届董事会由 9 名董事组成，其中非独立董事 5 名、独立董事 3 名、 职工代表董事 1 名，具体成员如下： 1、非独立董事：王旭先生（董事长）、曾妮女士、邵泽慧女士、曹芳女士、 方志刚先生； 1、审计委员会：曹纲先 ...

法律意见书 北京市中伦律师事务所 关于北京北陆药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：北京北陆药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为北京北陆药业股份有限公司 （以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2025年第 二次临时股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）《上市公司股东会规则》等相关法律、法规、规范性文件及《北 京北陆药业股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股 东大会进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 为出具本法律意见书，本所律师独立、 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-054 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 3、会议召集人：公司董事会 4、会议主持人：董事长、总经理 王旭 1 5、召开方式：本次会议采取现场投票和网络投票相结合的方式 一、会议召开和出席情况 1、会议召开的日期和时间： （1）现场会议召开时间为：2025年6月9日（星期一）下午14：00 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2025年6月9日9：15—9：25、9：30—11：30、13：00—15：00；通 过深圳证券交易所互联网投票系统投票的时间为2025年6月9日上午9：15至下 午15：00期间的任意时间。 2、召开地点：北京市海淀区西直门北大街 32 号枫蓝国际写字楼 A 座 7 层 A1 会议室 6、会议召开的合法 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-057 债券代码：123082 债券简称：北陆转债 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管 理办法》等法律法规、规范性文件及《公司章程》等公司治理制度的规定，公 1 北京北陆药业股份有限公司 第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第一次会 议于2025年6月9日下午以现场及通讯相结合的方式召开，会议通知以邮件方 式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参加表决 董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的有关规 定。会议由董事王旭先生主持，与会董事以记名投票方式审议通过了以下议 案： 一、关于选举第九届董事会董事长的议案 董事会同意选举王旭先生为公司第九届董事会董事长，任期自本次董事会 审议通过之日起至第九届董事会届满之日止。 表决结果：9 票同意，0 票反对，0 ...

| 股票代码：300016 | 股票简称：北陆药业 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123082 | 债券简称：北陆转债 | | 北京北陆药业股份有限公司 北京北陆药业股份有限公司 董事会 二○二五年六月九日 1 附件：职工代表董事简历 杨颖，女，1978 年出生，中国国籍，无境外永久居留权，本科。现任公司 总经理办公室副主任、北京天陆元投资管理有限公司董事、北京艾湃克斯医药 研发有限公司监事；曾任公司办公室行政助理、监事会主席、职工监事等。 关于选举第九届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第八届董事会任期已届 满，根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律法规、 规范性文件以及《公司章程》的相关规定，公司于2025年5月28日召开了职工 代表大会。经与会职工代表审议，同意选举杨颖女士为公司第九届董事会职工 代表董事（简历详见附件）。公司 ...

Group 1: Contrast Agent Product Strategy - The company has successfully integrated multiple contrast agent products into the national drug centralized procurement system, leading to significant changes in the competitive landscape and sales model of the industry, creating both challenges and opportunities [1] - The company has overcome challenges posed by price reductions in iodine contrast agents and is experiencing a recovery trend, with a focus on expanding market share for iodinated contrast agents [1] - The company has diversified its gadolinium-based contrast agents, with the approval of Gadobutrol injection in July 2024, enhancing its product offerings to meet various clinical needs [1] - In 2024, the contrast agent products achieved sales revenue of CNY 58,804.95 million, representing a year-on-year growth of 9.87% [2] Group 2: Jinlianhua Granule Procurement Progress - Jinlianhua Granule, a core product of Tianyuan Pharmaceutical, is a natural single-component preparation with applications in treating upper respiratory infections and is covered by national insurance [3] - The product is a unique offering in the market and has been included in procurement lists across multiple provinces, enhancing its market presence [3] Group 3: Medical Technology Focus - The company's subsidiary, Shenzhen Yiwei Medical Technology Co., Ltd., specializes in brain disease early screening, precise diagnosis, and rehabilitation training, making it a leader in the field of brain science AI [4] - Yiwei Medical's core products target stroke, Alzheimer's disease, cognitive disorders, and developmental disorders in youth, providing a comprehensive solution for brain disease management [4] Group 4: Yiwei Medical's Business Model - Yiwei Medical offers a full-service model from screening to rehabilitation for brain diseases, creating a closed-loop medical service system [6] - The company collaborates with health check institutions to provide a comprehensive "brain routine" health check package and has developed a unique diagnostic platform for neurodegenerative diseases [6] - Yiwei Medical is exploring additional business models to expand market coverage and increase revenue streams [6] Group 5: Zhiyou Medical Progress - Zhiyou Medical has received NMPA approval for its BCR/ABL and AML1/ETO fusion gene testing kits, marking a significant milestone in the field of blood cancer molecular diagnostics [7] - The approval solidifies Zhiyou Medical's position in the precision diagnosis of blood cancers and complements its existing product offerings for solid tumors [7][8] - The company has obtained nearly 200 NMPA certifications, covering various disease areas and advancing the FISH technology from high-end testing to clinical application [8]